Analyst consensus rating
Aligos Therapeutics Analyst Rating: none
Direct answer
Aligos Therapeutics's consensus rating is none.
8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $52.38.
Forecast evidence checked September 28, 2026.
Get free Aligos Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $5.36
- Average price target
- $52.38
- High price target
- $175.00
- Low price target
- $20.00
- Low target gap
- +273.5%
- Target upside
- +878.1%
- High target gap
- +3,168%
- Target range width
- 2,894.5%
- Consensus rating
- none
- Analysts
- 8
- Evidence date
- September 28, 2026
- Valid through
- October 5, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Aligos Therapeutics?
Aligos Therapeutics has a verified none consensus. The same dataset has an average price target of $52.38.
How far are Aligos Therapeutics's low and high targets from the recorded price?
The low target implies +273.5%, while the high target implies +3,168%.
How many analysts are included in Aligos Therapeutics's consensus?
The verified consensus includes 8 analysts.
How is Aligos Therapeutics's target upside or downside calculated?
The average target of $52.38 is divided by the recorded price of $5.36, then one is subtracted to produce +878.1%. This does not guarantee a future return.
When was Aligos Therapeutics's analyst forecast verified?
The data was verified on 2026-09-28. The dataset is valid through 2026-10-05.